Skip to main content
logo
VYNE Therapeutics Inc. (VYNE)
Jul 27, 2026 - VYNE was delisted (reason: merged with YARW)
28.56
+3.11 (12.22%)
Inactive · Last trade price on Jul 27, 2026

VYNE Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
19194933955
Market Cap Growth
-21.70%-60.93%51.96%273.57%-84.05%-79.42%
Enterprise Value
-6-13-2117-273
Last Close Price
28.5616.3694.5065.7376.17517.93

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
41.9633.8898.6476.7018.2558.63
PB Ratio
0.770.700.950.370.281.12
P/TBV Ratio
0.770.700.950.370.281.12

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
---40.27-3.58

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
--0.000.00-0.01
Net Debt / Equity Ratio
-1.01-1.04-1.18-1.05-0.98-0.86
Net Debt / EBITDA Ratio
1.020.981.413.190.901.08
Net Debt / FCF Ratio
0.970.881.803.671.060.74
Asset Turnover
0.010.010.010.010.010.01
Quick Ratio
20.1712.114.1512.373.842.71
Current Ratio
20.8712.534.3512.734.103.43
Return on Equity (ROE)
-63.16%-66.97%-56.54%-46.40%-84.81%-102.66%
Return on Assets (ROA)
-37.01%-38.31%-33.14%-26.42%-39.77%-30.25%
Return on Capital Employed (ROCE)
-98.90%-107.10%-83.80%-32.50%-109.20%-80.00%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-112.63%-137.15%-80.61%-87.49%-266.62%-134.33%
FCF Yield
-135.13%-171.54%-68.98%-77.92%-335.43%-103.26%
Buyback Yield / Dilution
-0.42%-0.42%-314.57%-222.44%-11.44%-58.75%
SEC Filings: 10-K · 10-Q